Amarin Corporation plc · NASDAQ (us_market)
Healthcare · Drug Manufacturers - General · Ireland
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-10-20$20.25 RISE2026-02-27$13.80 PEAK2026-03-12$16.37 143d | -31.9% 130d | Missed | Missed | — | — | +18.6% 13d | Missed |
DROP2025-10-20$20.25 RISE2026-01-05$13.50 PEAK2026-01-22$16.51 94d | -33.3% 77d | Missed | Missed | — | — | +22.3% 17d | Missed |
DROP2025-07-09$17.33 RISE2025-09-17$14.60 PEAK2025-10-20$20.25 103d | -15.8% 70d | Missed | Missed | — | — | +38.7% 33d | Missed |
DROP2025-07-09$17.33 RISE2025-07-31$14.52 PEAK2025-10-20$20.25 103d | -16.2% 22d | Missed | Missed | — | — | +39.5% 81d | Missed |
DROP2025-01-23$12.80 RISE2025-04-04$8.00 PEAK2025-07-01$16.81 159d | -37.5% 71d | Missed | Missed | — | — | +110.1% 88d | Missed |
DROP2025-01-23$12.80 RISE2025-03-12$8.00 PEAK2025-06-06$12.72 134d | -37.5% 48d | Missed | Missed | — | — | +59.0% 86d | Missed |
DROP2024-08-21$13.00 RISE2024-12-30$8.80 PEAK2025-01-23$12.80 155d | -32.3% 131d | Missed | Missed | — | — | +45.5% 24d | Missed |
DROP2024-08-19$13.40 RISE2024-12-23$8.80 PEAK2025-01-23$12.80 157d | -34.3% 126d | Missed | Missed | — | — | +45.5% 31d | Missed |
DROP2024-02-27$27.00 RISE2024-06-10$12.60 PEAK2024-06-12$16.20 106d | -53.3% 104d | Missed | Missed | — | — | +28.6% 2d | Missed |
DROP2024-02-27$27.00 RISE2024-05-01$16.80 PEAK2024-05-06$19.60 69d | -37.8% 64d | Missed | Missed | — | — | +16.7% 5d | Missed |
DROP2024-02-27$27.00 RISE2024-03-14$16.40 PEAK2024-04-08$21.40 41d | -39.3% 16d | Missed | Missed | — | — | +30.5% 25d | Missed |
DROP2023-07-31$24.00 RISE2023-12-04$14.00 PEAK2024-01-29$27.00 182d | -41.7% 126d | Missed | Missed | — | — | +92.9% 56d | Missed |
DROP2023-07-18$28.60 RISE2023-11-02$13.20 PEAK2024-01-29$27.00 195d | -53.8% 107d | Missed | Missed | — | — | +104.5% 88d | Missed |
DROP2022-08-16$33.40 RISE2022-11-28$22.40 PEAK2023-02-07$43.80 175d | -32.9% 104d | Missed | Missed | — | — | +95.5% 71d | Missed |
DROP2022-06-23$39.80 RISE2022-10-19$21.40 PEAK2023-01-13$41.80 204d | -46.2% 118d | Missed | Missed | — | — | +95.3% 86d | Missed |
1–15 / 26 1 / 2 | |||||||
No scored news yet for a sentiment trend.
European equities traded in the US as American depositary receipts were trending slightly lower late
New REDUCE-IT data presented at EAS 2026 suggests risk-weighted apoB could better identify residual cardiovascular risk in statin-treated patients with elevated triglycerides. Key Investor TakeawaysAmarin (NASDAQ:AMRN) presented new REDUCE-IT findings linking risk-weighted apoB to improved cardiovascular risk prediction in statin-treated patients.
Amarin Corporation plc (NASDAQ:AMRN) (Amarin), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced new data from a post hoc analysis of the REDUCE-IT® trial
European equities traded in the US as American depositary receipts were trending higher late Tuesday
Amarin’s target fair value has been adjusted from US$12.00 to US$12.50 per share, a small but telling move that has caught investor attention. Analysts are framing this US$0.50 shift as a refinement of their view, reflecting a mix of optimism on execution and caution around longer term growth and valuation risk. Read on to see what is driving the debate and how you can track the evolving story around this stock. Stay updated as the Fair Value for Amarin shifts by adding it to your watchlist...
European equities traded in the US as American depositary receipts were heading higher late Monday m
KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.
CorMedix beats Q1 estimates as DefenCath demand surges and raises 2026 guidance on stronger execution and growing profitability.
European equities traded in the US as American depositary receipts were moving higher late Thursday
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
ALT posts a narrower Q1 loss as pemvidutide advances in MASH, AUD and ALD studies, with the cash runway now expected to extend into 2029.
Amarin Pharma convinced a U.S.appeals court on Tuesday to resurrect a patent infringementlawsuit over Hikma Pharmaceuticals' generic version of Amarin'scardiovascular drug Vascepa. ...
Presentation Operator MessageOperator Good day, ladies and gentlemen, and welcome to the Amarin Corporation's First Quarter 2026 Results Conference Call. [Operator Instructions] And please note,
Amarin Corporation plc (AMRN) Q1 2026 Earnings Call April 29, 2026 8:00 AM EDTCompany ParticipantsDevin SullivanAaron Berg - CEO, President &...
Amarin's Q1 2026 revenue beat estimates at $45.1M, but EPS missed with a $0.09 loss. Positive cash flow and cost-cutting offset restructuring charges, with shares up slightly in pre-market trading.
DUBLIN — DUBLIN — Amarin Corp. PLC on Wednesday reported a loss of $10.5 million in its first quarter. On a per-share basis, the Dublin-based company said it had a loss of 60 cents. Losses,...
Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $45.132 million which beat the analyst consensus estimate of $43.771 million by 3.11 percent. This is a 7.41 percent increase over sales of $42.017 million the same
Total Revenue Increased Led by Higher International Sales Generated Positive Cash Flow and Reiterates Expectation for Full Year Positive Cash Flow Recently Updated Industry Guidelines Expand Global...
DUBLIN and BRIDGEWATER, N.J., April 15, 2026 -- Amarin Corporation plc , a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will report first quarter...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| AMRN | +2.99% | +4.02% | +3.80% | +25.02% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +0.02% | +9.74% | +7.24% | +12.33% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Citadel | multi-strat | 240.8K | $3.48M | 0.00% | Added+559.8% | 2026-03-31 |
| TwoSigma | quant | 107.5K | $1.56M | 0.00% | Trimmed-3.3% | 2026-03-31 |
| StateStreet | passive | 24.9K | $360.76K | 0.00% | Added+4.5% | 2026-03-31 |
| RenTech | quant | 19.3K | $278.44K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-29upcoming | -0.10 | — | — |
| 2026-04-29 | 0.01 | -0.03 | -400.00% |
| 2026-02-25 | 0.07 | 0.01 | -85.71% |
| 2025-10-29 | — | 0.19 | — |
| 2025-07-30 | -0.61 | 0.87 | +242.62% |
| 2025-05-07 | -0.77 | -0.80 | -3.90% |
| 2025-03-12 | -0.60 | -0.40 | +33.33% |
| 2024-10-30 | -1.20 | -1.00 | +16.67% |
| 2024-07-31 | -1.20 | 0.20 | +116.67% |
| 2024-05-01 | -0.60 | -0.20 | +66.67% |
| 2024-02-29 | -0.50 | — | +100.00% |
| 2023-11-01 | -0.40 | — | +100.00% |
| 2023-08-02 | -0.60 | 0.40 | +166.67% |
| 2023-05-03 | -0.27 | 0.40 | +250.00% |
| 2023-03-01 | 0.08 | 0.04 | -50.00% |
| 2022-10-27 | -1.25 | 0.07 | +105.60% |